Propeller Health’s Digital Health Platform Cleared For Use With Symbicort Inhaler

Propeller Health’s digital health tool has received an additional clearance from the U.S. Food and Drug Administration, allowing it to be used to collect data from consumers using AstraZeneca’s Symbicort inhaler. The system is designed to help consumers manage their asthma and chronic obstructive pulmonary disease (COPD).

The system uses sensors to analyze an individual's inhaler use and sends the data to the company’s Propeller smartphone app, which they can then share with clinicians. The platform was previously cleared to connect to many other inhalers used by individuals with asthma and COPD, including products made . . .